Skip to main content

Table 1 Demographics, clinical presentation and management grouped by platelet count at onset of S. aureus bacteremia

From: Prognostic significance of early platelet dynamics in Staphylococcus aureus bacteremia

 

All patients

N = 811

NP (≥ 150 × 109/L)

n = 577

TC (< 150 × 109/L)

n = 234

p-value

(NP vs TC)

Age, years, median (IQR)

59 (47, 70)

58 (47, 69)

59 (49, 72)

0.15

Male

577 (71)

416 (72)

161 (69)

0.35

Comorbidities

 Coronary artery disease

94 (12)

54 (9)

40 (17)

0.002

 Diabetes

350 (43)

259 (45)

91 (39)

0.12

 Hypertension

402 (50)

287 (50)

115 (49)

0.88

 Intravenous drug use

97 (12)

73 (13)

24 (10)

0.34

 Alcohol use disorder

117 (14)

72 (12)

45 (19)

0.01

 Active malignancy

79 (10)

44 (8)

35 (15)

0.001

 Liver disease

123 (15)

57 (10)

66 (28)

 < 0.0001

 Cirrhosis

82 (10)

24 (4)

58 (25)

 < 0.0001

 Renal disease

213 (26)

140 (24)

73 (31)

0.04

Community Onset of SAB

677 (83)

492 (85)

185 (79)

0.03

MRSA as causative pathogen

277 (34)

207 (36)

70 (30)

0.10

Source risk category

 < 0.0001

 Low

166 (20)

104 (18)

62 (27)

 

 Intermediate

469 (58)

372 (64)

97 (41)

 

 High

176 (22)

101 (18)

75 (32)

 

Infection type related to SAB

 Endocarditis

73 (9)

34 (6)

39 (17)

 < 0.0001

 Pneumonia

69 (9)

46 (8)

23 (10)

0.39

 Osteomyelitis

101 (12)

87 (15)

14 (6)

0.0004

Metastatic Complications^

176 (22)

127 (22)

49 (21)

0.72

Severity of Illness

 Pitt Bacteremia Score,median (IQR)^

1.0 (0, 2.0)

1.0 (0, 2.0)

1.0 (0, 3.0)

0.0003

 Severe sepsis^

363 (45)

209 (37)

154 (67)

 < 0.0001

 Septic shock^

104 (13)

61 (11)

43 (18)

0.003

 ICU stay^

269 (33)

168 (29)

101 (43)

0.0001

Source control procedure not performed

452 (56)

300 (52)

152 (65)

 < 0.001

Initial anti-staphylococcal regimen

 Vancomycin-containing regimen

597 (74)

428 (74)

169 (72)

0.57

 Linezolid-containing regimen

37 (5)

32 (6)

5 (2)

0.04

Time to start of effective anti-staphylococcal therapy

0.88

 On or before day of SAB onset

567 (70)

404 (70)

163 (70)

 

 Within 24 h of SAB onset

220 (27)

156 (27)

64 (28)

 

 Within 48 h of SAB onset

21 (3)

16 (3)

5 (2)

 

Concurrent antiplatelet therapy*

199 (25)

140 (24)

59 (25)

0.78

Aspirin

193 (24)

135 (23)

58 (25)

0.67

Clopidogrel

35 (4)

25 (4)

10 (4)

0.97

  1. ICU: intensive care unit; IQR: interqartile range; NP: normal platelet; SAB: S. aureus bacteremia; TC: thrombocytopenia
  2. Data are no. (%) unless otherwise indicated
  3. *Aspirin, clopidogrel, aspirin-dipyridamole; ^data may not add up to N = 811 due to missing data